Assembly and Maintenance of Sarcomere Thin Filaments and Associated Diseases
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Supplemental Figure 1. Vimentin
Double mutant specific genes Transcript gene_assignment Gene Symbol RefSeq FDR Fold- FDR Fold- FDR Fold- ID (single vs. Change (double Change (double Change wt) (single vs. wt) (double vs. single) (double vs. wt) vs. wt) vs. single) 10485013 BC085239 // 1110051M20Rik // RIKEN cDNA 1110051M20 gene // 2 E1 // 228356 /// NM 1110051M20Ri BC085239 0.164013 -1.38517 0.0345128 -2.24228 0.154535 -1.61877 k 10358717 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 /// BC 1700025G04Rik NM_197990 0.142593 -1.37878 0.0212926 -3.13385 0.093068 -2.27291 10358713 NM_197990 // 1700025G04Rik // RIKEN cDNA 1700025G04 gene // 1 G2 // 69399 1700025G04Rik NM_197990 0.0655213 -1.71563 0.0222468 -2.32498 0.166843 -1.35517 10481312 NM_027283 // 1700026L06Rik // RIKEN cDNA 1700026L06 gene // 2 A3 // 69987 /// EN 1700026L06Rik NM_027283 0.0503754 -1.46385 0.0140999 -2.19537 0.0825609 -1.49972 10351465 BC150846 // 1700084C01Rik // RIKEN cDNA 1700084C01 gene // 1 H3 // 78465 /// NM_ 1700084C01Rik BC150846 0.107391 -1.5916 0.0385418 -2.05801 0.295457 -1.29305 10569654 AK007416 // 1810010D01Rik // RIKEN cDNA 1810010D01 gene // 7 F5 // 381935 /// XR 1810010D01Rik AK007416 0.145576 1.69432 0.0476957 2.51662 0.288571 1.48533 10508883 NM_001083916 // 1810019J16Rik // RIKEN cDNA 1810019J16 gene // 4 D2.3 // 69073 / 1810019J16Rik NM_001083916 0.0533206 1.57139 0.0145433 2.56417 0.0836674 1.63179 10585282 ENSMUST00000050829 // 2010007H06Rik // RIKEN cDNA 2010007H06 gene // --- // 6984 2010007H06Rik ENSMUST00000050829 0.129914 -1.71998 0.0434862 -2.51672 -
Impairments in Contractility and Cytoskeletal Organisation Cause Nuclear Defects in Nemaline Myopathy
bioRxiv preprint doi: https://doi.org/10.1101/518522; this version posted January 28, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Impairments in contractility and cytoskeletal organisation cause nuclear defects in nemaline myopathy Jacob A Ross1, Yotam Levy1, Michela Ripolone2, Justin S Kolb3, Mark Turmaine4, Mark Holt5, Maurizio Moggio2, Chiara Fiorillo6, Johan Lindqvist3, Nicolas Figeac5, Peter S Zammit5, Heinz Jungbluth5,7,8, John Vissing9, Nanna Witting9, Henk Granzier3, Edmar Zanoteli10, Edna C Hardeman11, Carina Wallgren- Pettersson12, Julien Ochala1,5. 1. Centre for Human & Applied Physiological Sciences, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, Guy’s Campus, King’s College London, SE1 1UL, UK 2. Neuromuscular and Rare Diseases Unit, Department of Neuroscience, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan 20122, Italy 3. Department of Cellular and Molecular Medicine, University of Arizona, Tucson, Arizona, 85721, USA 4. Division of Biosciences, University College London, Gower Street, London WC1E 6BT, UK 5. Randall Centre for Cell and Molecular Biophysics, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, Guy’s Campus, King’s College London, SE1 1UL, UK 6. Molecular Medicine, IRCCS Fondazione Stella Maris, Pisa and Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genoa, Italy 7. Department of Paediatric Neurology, Neuromuscular Service, Evelina's Children Hospital, Guy's and St Thomas' Hospital National Health Service Foundation Trust, London, SE1 9RT, UK 8. Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King's College, London, SE1 1UL, UK 9. -
Tropomodulin Isoform-Specific Regulation of Dendrite Development and Synapse Formation
This Accepted Manuscript has not been copyedited and formatted. The final version may differ from this version. Research Articles: Cellular/Molecular Tropomodulin Isoform-Specific Regulation of Dendrite Development and Synapse Formation Omotola F. Omotade1,3, Yanfang Rui1,3, Wenliang Lei1,3, Kuai Yu1, H. Criss Hartzell1, Velia M. Fowler4 and James Q. Zheng1,2,3 1Department of Cell Biology, Emory University School of Medicine, Atlanta, GA 30322. 2Department of Neurology 3Center for Neurodegenerative Diseases, Emory University School of Medicine, Atlanta, GA 30322. 4Department of Molecular Medicine, Scripps Research Institute, La Jolla, CA 92037 DOI: 10.1523/JNEUROSCI.3325-17.2018 Received: 22 November 2017 Revised: 25 September 2018 Accepted: 2 October 2018 Published: 9 October 2018 Author contributions: O.F.O. and J.Q.Z. designed research; O.F.O., Y.R., W.L., and K.Y. performed research; O.F.O. and J.Q.Z. analyzed data; O.F.O. and J.Q.Z. wrote the paper; Y.R., H.C.H., V.M.F., and J.Q.Z. edited the paper; V.M.F. contributed unpublished reagents/analytic tools. Conflict of Interest: The authors declare no competing financial interests. This research project was supported in part by research grants from National Institutes of Health to JQZ (GM083889, MH104632, and MH108025), OFO (5F31NS092437-03), VMF (EY017724) and HCH (EY014852, AR067786), as well as by the Emory University Integrated Cellular Imaging Microscopy Core of the Emory Neuroscience NINDS Core Facilities grant (5P30NS055077). We would like to thank Dr. Kenneth Myers for his technical expertise and help throughout the project. We also thank Drs. -
Stockholm University
Stockholm University This is a published version of a paper published in Journal of Molecular Biology. Citation for the published paper: Björklund, Å., Light, S., Sagit, R., Elofsson, A. (2010) "Nebulin: A Study of Protein Repeat Evolution" Journal of Molecular Biology, 402(1): 38-51 URL: http://dx.doi.org/10.1016/j.jmb.2010.07.011 Access to the published version may require subscription. Permanent link to this version: http://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-50177 http://su.diva-portal.org RGR YJMBI-62434; No. of pages: 14; 4C: 2, 5, 8, 9 doi:10.1016/j.jmb.2010.07.011 J. Mol. Biol. (2010) xx, xxx–xxx Available online at www.sciencedirect.com Nebulin: A Study of Protein Repeat Evolution Åsa K. Björklund, Sara Light†, Rauan Sagit† and Arne Elofsson⁎ Center for Biological Membrane Protein domain repeats are common in proteins that are central to the Research, Stockholm organization of a cell, in particular in eukaryotes. They are known to evolve Bioinformatics Center, through internal tandem duplications. However, the understanding of the Department of Biochemistry and underlying mechanisms is incomplete. To shed light on repeat expansion Biophysics, Stockholm mechanisms, we have studied the evolution of the muscle protein Nebulin, University, Stockholm, Sweden a protein that contains a large number of actin-binding nebulin domains. Nebulin proteins have evolved from an invertebrate precursor containing Received 30 March 2010; two nebulin domains. Repeat regions have expanded through duplications received in revised form of single domains, as well as duplications of a super repeat (SR) consisting 22 June 2010; of seven nebulins. -
Serum Albumin OS=Homo Sapiens
Protein Name Cluster of Glial fibrillary acidic protein OS=Homo sapiens GN=GFAP PE=1 SV=1 (P14136) Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 Cluster of Isoform 3 of Plectin OS=Homo sapiens GN=PLEC (Q15149-3) Cluster of Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 (P68871) Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 Cluster of Tubulin beta-3 chain OS=Homo sapiens GN=TUBB3 PE=1 SV=2 (Q13509) Cluster of Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 (P60709) Cluster of Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 (P68363) Cluster of Isoform 2 of Spectrin alpha chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTAN1 (Q13813-2) Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 Cluster of Spectrin beta chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTBN1 PE=1 SV=2 (Q01082) Cluster of Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM PE=1 SV=4 (P14618) Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 Cytoplasmic dynein 1 heavy chain 1 OS=Homo sapiens GN=DYNC1H1 PE=1 SV=5 Cluster of ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide OS=Homo sapiens GN=ATP1A2 PE=3 SV=1 (B1AKY9) Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 Dihydropyrimidinase-related protein 2 OS=Homo sapiens GN=DPYSL2 PE=1 SV=1 Cluster of Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 (P12814) 60 kDa heat shock protein, mitochondrial OS=Homo -
2020 Program Book
PROGRAM BOOK Note that TAGC was cancelled and held online with a different schedule and program. This document serves as a record of the original program designed for the in-person meeting. April 22–26, 2020 Gaylord National Resort & Convention Center Metro Washington, DC TABLE OF CONTENTS About the GSA ........................................................................................................................................................ 3 Conference Organizers ...........................................................................................................................................4 General Information ...............................................................................................................................................7 Mobile App ....................................................................................................................................................7 Registration, Badges, and Pre-ordered T-shirts .............................................................................................7 Oral Presenters: Speaker Ready Room - Camellia 4.......................................................................................7 Poster Sessions and Exhibits - Prince George’s Exhibition Hall ......................................................................7 GSA Central - Booth 520 ................................................................................................................................8 Internet Access ..............................................................................................................................................8 -
Cardiomyopathy Precision Panel Overview Indications
Cardiomyopathy Precision Panel Overview Cardiomyopathies are a group of conditions with a strong genetic background that structurally hinder the heart to pump out blood to the rest of the body due to weakness in the heart muscles. These diseases affect individuals of all ages and can lead to heart failure and sudden cardiac death. If there is a family history of cardiomyopathy it is strongly recommended to undergo genetic testing to be aware of the family risk, personal risk, and treatment options. Most types of cardiomyopathies are inherited in a dominant manner, which means that one altered copy of the gene is enough for the disease to present in an individual. The symptoms of cardiomyopathy are variable, and these diseases can present in different ways. There are 5 types of cardiomyopathies, the most common being hypertrophic cardiomyopathy: 1. Hypertrophic cardiomyopathy (HCM) 2. Dilated cardiomyopathy (DCM) 3. Restrictive cardiomyopathy (RCM) 4. Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 5. Isolated Left Ventricular Non-Compaction Cardiomyopathy (LVNC). The Igenomix Cardiomyopathy Precision Panel serves as a diagnostic and tool ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes. Indications The Igenomix Cardiomyopathy Precision Panel is indicated in those cases where there is a clinical suspicion of cardiomyopathy with or without the following manifestations: - Shortness of breath - Fatigue - Arrythmia (abnormal heart rhythm) - Family history of arrhythmia - Abnormal scans - Ventricular tachycardia - Ventricular fibrillation - Chest Pain - Dizziness - Sudden cardiac death in the family 1 Clinical Utility The clinical utility of this panel is: - The genetic and molecular diagnosis for an accurate clinical diagnosis of a patient with personal or family history of cardiomyopathy, channelopathy or sudden cardiac death. -
1 Demographic History, Cold Adaptation, and Recent NRAP Recurrent Convergent Evolution At
bioRxiv preprint doi: https://doi.org/10.1101/2020.06.15.151894; this version posted June 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Demographic history, cold adaptation, and recent NRAP recurrent convergent evolution at 2 amino acid residue 100 in the world northernmost cattle from Russia 3 4 Laura Buggiotti1, Andrey A. Yurchenko2, Nikolay S. Yudin2, Christy J. Vander Jagt3, Hans D. 5 Daetwyler3,4, Denis M. Larkin1,2,5 6 1Royal Veterinary College, University of London, London, UK. 7 2The Federal State Budgetary Institution of Science Federal Research Center Institute of Cytology 8 and Genetics, Siberian Branch of the Russian Academy of Sciences (ICG SB RAS), Novosibirsk, 9 Russia. 10 3Agriculture Victoria, AgriBio, Centre for AgriBioscience, Bundoora, 3083, Victoria, Australia. 11 4School of Applied Systems Biology, La Trobe University, Bundoora, 3083, Victoria, Australia. 12 5Kurchatov Genomics Center, the Federal Research Center Institute of Cytology and Genetics, 13 Siberian Branch of the Russian Academy of Science, Novosibirsk, Russia. 14 15 Abstract 16 Native cattle breeds represent an important cultural heritage. They are a reservoir of genetic variation 17 useful for properly responding to agriculture needs in light of ongoing climate changes. Evolutionary 18 processes that occur in response to extreme environmental conditions could also be better understood 19 using adapted local populations. Herein, different evolutionary histories for two of the world 20 northernmost native cattle breeds from Russia were investigated. They highlighted Kholmogory as a 21 typical taurine cattle, while Yakut cattle separated from European taurines ~5,000 years ago and 22 contain numerous ancestral and some novel genetic variants allowing their adaptation to harsh 23 conditions of living above the Polar Circle. -
The Functional Role of NRAP in the Nucleolus
The Functional Role of NRAP in the Nucleolus Author Inder, Kerry Published 2006 Thesis Type Thesis (PhD Doctorate) School School of Biomolecular and Biomedical Sciences DOI https://doi.org/10.25904/1912/3452 Copyright Statement The author owns the copyright in this thesis, unless stated otherwise. Downloaded from http://hdl.handle.net/10072/367738 Griffith Research Online https://research-repository.griffith.edu.au THE FUNCTIONAL ROLE OF NRAP IN THE NUCLEOLUS Presented by Kerry Inder, B Biomed Sci. (Hons) A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy School of Biomolecular and Biomedical Science And Natural Product Discovery Faculty of Science, Griffith University, Brisbane, Australia Submitted March, 2006 I STATEMENT OF ORIGINALITY The material presented in this thesis has not previously been submitted for a degree in any university. To the best of my knowledge and belief, the thesis contains no material previously published or written by another person except where due reference is made in the thesis itself. Kerry Inder. II PUBLICATIONS AND ABSTRACTS ARISING FROM THIS STUDY PUBLICATIONS Inder, K.L., Utama, B., Gan, Y., Wang, X., and Kennedy, D. Nrap/Nol6 is involved in rRNA processing through the regulation of B23/NPM and p19ARF. (submitted) ABSTRACTS Inder, K.L., Utama, B., Gan, Y., Wang, X., and Kennedy, D. Nrap/Nol6 is involved in rRNA processing through the regulation of B23/NPM and p19ARF., ComBio Combined Conference, Adelaide, Australia, 2005. (oral presentation) Hartmann, B., Aitken, K.L., Utama, B., Kennedy, D. Nrap, a novel nucleolar protein which interacts with B23/Nucleophosmin during ribosome biogenesis. -
RENAL TUMOURS to Be Used in Conjunction with the Umbrella Study Protocol
CLINICAL MANAGEMENT GUIDELINES RENAL TUMOURS To be used in conjunction with the Umbrella Study Protocol Dr Sucheta J Vaidya Dr Lisa Howell Dr Tanzina Chowdhury Dr Minou Oostveen Dr Cat Duncan Mr Mark Powis Mr Bruce Okoye Dr Daniel Saunders Professor Gordan Vujanic Professor Kathy Pritchard Jones On behalf of the CCLG Renal Tumour Special Interest Group January 2020 The CCLG does not sponsor or indemnify the treatment detailed herein. These treatment recommendations are provided by the CCLG Renal Tumours Special Interest Group to inform and for use at the sole discretion of treating clinicians who retain professional responsibility for their actions and treatment decisions. Treatment recommendations are based on current best practice and not what is necessarily proposed for any forthcoming clinical trial. CCLG Clinical Management Guidelines: Renal Tumours - January 2020 1 [This page is blank on purpose] CCLG Clinical Management Guidelines: Renal Tumours - January 2020 2 TABLE OF CONTENTS 1. Background and Rationale ............................................................................................. 8 2. Specific Objectives of CCLG Clinical Guidelines ............................................................. 10 3. Guideline Recommendations ....................................................................................... 10 3.1 Diagnostic work up guidelines for renal tumours ................................................................. 10 Clinical work-up .......................................................................................................................................... -
Identification of the Fatty Acid Synthase Interaction Network Via Itraq-Based Proteomics Indicates the Potential Molecular Mecha
Huang et al. Cancer Cell Int (2020) 20:332 https://doi.org/10.1186/s12935-020-01409-2 Cancer Cell International PRIMARY RESEARCH Open Access Identifcation of the fatty acid synthase interaction network via iTRAQ-based proteomics indicates the potential molecular mechanisms of liver cancer metastasis Juan Huang1, Yao Tang1, Xiaoqin Zou1, Yi Lu1, Sha She1, Wenyue Zhang1, Hong Ren1, Yixuan Yang1,2* and Huaidong Hu1,2* Abstract Background: Fatty acid synthase (FASN) is highly expressed in various types of cancer and has an important role in carcinogenesis and metastasis. To clarify the mechanisms of FASN in liver cancer invasion and metastasis, the FASN protein interaction network in liver cancer was identifed by targeted proteomic analysis. Methods: Wound healing and Transwell assays was performed to observe the efect of FASN during migration and invasion in liver cancer. Isobaric tags for relative and absolute quantitation (iTRAQ)-based mass spectrometry were used to identify proteins interacting with FASN in HepG2 cells. Diferential expressed proteins were validated by co-immunoprecipitation, western blot analyses and confocal microscopy. Western blot and reverse transcription- quantitative polymerase chain reaction (RT-qPCR) were performed to demonstrate the mechanism of FASN regulating metastasis. Results: FASN knockdown inhibited migration and invasion of HepG2 and SMMC7721 cells. A total of, 79 proteins interacting with FASN were identifed. Additionally, gene ontology term enrichment analysis indicated that the majority of biological regulation and cellular processes that the FASN-interacting proteins were associated with. Co- precipitation and co-localization of FASN with fascin actin-bundling protein 1 (FSCN1), signal-induced proliferation- associated 1 (SIPA1), spectrin β, non-erythrocytic 1 (SPTBN1) and CD59 were evaluated. -
A Systems-Wide Screen Identifies Substrates of the SCF Ubiquitin Ligase
RESEARCH RESOURCE PROTEOMICS A systems-wide screen identifies substrates of the SCFbTrCP ubiquitin ligase Teck Yew Low,1,2 Mao Peng,1,2* Roberto Magliozzi,3* Shabaz Mohammed,1,2† Daniele Guardavaccaro,3 Albert J. R. Heck1,2‡ Cellular proteins are degraded by the ubiquitin-proteasome system (UPS) in a precise and timely fashion. Such precision is conferred by the high substrate specificity of ubiquitin ligases. Identification of substrates of ubiquitin ligases is crucial not only to unravel the molecular mechanisms by which the UPS controls protein degradation but also for drug discovery purposes because many established UPS substrates are implicated in disease. We developed a combined bioinformatics and affinity purification– mass spectrometry (AP-MS) workflow for the system-wide identification of substrates of SCFbTrCP,a member of the SCF family of ubiquitin ligases. These ubiquitin ligases are characterized by a multi- subunit architecture typically consisting of the invariable subunits Rbx1, Cul1, and Skp1, and one of 69 F-box proteins. The F-box protein of this member of the family is bTrCP. SCFbTrCP binds, through the WD40 b repeats of TrCP, to the DpSGXX(X)pS diphosphorylated motif in its substrates. We recovered 27 pre- Downloaded from viously reported SCFbTrCP substrates, of which 22 were verified by two independent statistical proto- cols, thereby confirming the reliability of this approach. In addition to known substrates, we identified 221 proteins that contained the DpSGXX(X)pS motif and also interacted specifically with the WD40 repeats of bTrCP. Thus, with SCFbTrCP, as the example, we showed that integration of structural infor- mation, AP-MS, and degron motif mining constitutes an effective method to screen for substrates of ubiquitin ligases.